Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

Samsung Medical Center

Status and phase: Completed; Phase 4

Conditions: Polypoidal Choroidal Vasculopathy Without Active Polyp

Treatments: Drug: aflibercept

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02072408

2013-10-044-002

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.

Enrollment: 46 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• polypoidal choroidal vasculopathy without active polyp
• decreased visual acuity by subretinal fluid and hemorrhage involving foveal center

Exclusion criteria

• polypoidal choroidal vasculopathy with active polyp
• previous photodynamic therapy more than three times
• anti-VEGF injection within one month
• photodynamic therapy or intraocular steroid treatment within three months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

46 participants in 1 patient group

polypoidal choroidal vasculopathy without polyp

Experimental group

Treatment:

Drug: aflibercept